SHI Yuqing 1,2,3,4,5 , DIAO Sha 2,3,4,5 , ZENG Linan 2,3,4,5 , YI Qiusha 2,3,4,5 , LI Hailong 2,3,4,5 , YANG Xice 6 , HE Miao 7 , GUO Jiaping 8 , HUANG Chao 9 , WANG Qiang 9 , ZHANG Lingli 2,3,4,5,10
  • 1. West China School of Pharmacy, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 3. Evidence-based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 4. NMPA Key Laboratory for Technical Research on Drug Products in vitro and in vivo Correlation, Chengdu 610041, P. R. China;
  • 5. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu 610041, P. R. China;
  • 6. West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 7. Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi 435000, P. R. China;
  • 8. The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, P. R. China;
  • 9. Medical Management Service Guidance Center, National Health Commission of the People’s Republic of China, Beijing 100044, P. R. China;
  • 10. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
WANG Qiang, Email: jason2019@sina.cn; ZHANG Lingli, Email: zhanglingli@scu.edu.cn
Export PDF Favorites Scan Get Citation

Objective To systematically review the clinical applicability of the global guidelines evaluation index system, and to provide some foundation for the evidence-based establishment of the clinical applicability evaluation index system in China. Methods The PubMed, Embase, Cochrane Library, CNKI, WanFang and VIP databases were electronically searched to collect literature on the clinical applicability evaluation index system of guidelines from inception to November 2022. Two reviewers independently screened literature, extracted data and then organized the data to form the evaluation items pool through qualitative systematic review and thematic synthesis. Results A total of 82 articles were finally included, and 141 clinical applicability evaluation indicators were obtained, including 5 third-level topics, 14 analytical topics and 141 descriptive topics. The third-level topics were availability, readability, feasibility, acceptability and overall evaluation. Influencing factors in the feasibility field were summarized as medical staff factors, patient/patient family factors, environmental factors and guideline factors. Conclusion This study systematically sort out the applicability evaluation items of the guidelines, which provide an evidence-based reference for the construction of relevant evaluation index systems in China.

Citation: SHI Yuqing, DIAO Sha, ZENG Linan, YI Qiusha, LI Hailong, YANG Xice, HE Miao, GUO Jiaping, HUANG Chao, WANG Qiang, ZHANG Lingli. Clinical applicability of guidelines evaluation index system: a systematic review. Chinese Journal of Evidence-Based Medicine, 2024, 24(1): 61-68. doi: 10.7507/1672-2531.202306030 Copy

  • Previous Article

    Efficacy of PDA in the selection of treatment modalities for patients with end-stage renal disease: a systematic review
  • Next Article

    Research on quantitative evaluation of physical-medical integration policy based on PMC index model